Clinical TrialsSearch results
Number of results: 1194
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer.
- extensive disease small-cell lung cancer
- West Japan Oncology Group
- 2005-09-05
Other
- Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancer
- non-small cell lung cancer
- West Japan Oncology Group
- 2005-09-09
Other
- phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.
- lung adenocarcinoma
- West Japan Oncology Group
- 2005-09-08
Other
- Phase II study of Combination of CPT-11 and S-1 for Advanced Non-Small-cell lung cancer
- Previously untreated stageIIIB/IV NSCLC
- West Japan Oncology Group
- 2006-05-04
Other
- Phase II Study of Amrubicin in Patients with Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
- All patients had histologocally or cytologically confirmed locally advanced (non-irradiated) or metastatic NSCLC, with failure of platinum-based chemotherapy (exception for UFT and gefitinib).
- West Japan Oncology Group
- 2005-08-22
Other
- Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer
- Non-small cell lung cancer
- West Japan Oncology Group
- 2009-03-17
Other
- Phase 3 study of docetaxel vs vinorelbine in elderly patients with advanced non-small cell lung cancer
- elderly patients with advanced non-small cell lung cancer
- West Japan Oncology Group
- 2005-09-06
Other
- Lung Cancer Evaluation of TS-1 Study
- Previously untreated stageIIIB/IV NSCLC
- West Japan Oncology Group
- 2006-10-18
Other
- Immunohistochemical analysis of EGFR, HER2 and their phosphorylated status, and Insulin-like growth factor-1 receptor in tumor tissues obtained from non-small cell lung cancer patients treated with gefitinib
- gefitinib in patients with NSCLC
- West Japan Oncology Group
- 2005-09-07
Other
- Exploratory analysis of predictive and prognostic biomarkers in the randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (WJOG4407GTR)
- metastatic colorectal cancer
- West Japan Oncology Group
- 2009-06-02